Trial Profile
Phase II Trial of Maintenance Rituximab Plus FavId and GM-CSF Immunotherapy in Patients With Treatment-Naive Indolent B-Cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Mitumprotimut T (Primary) ; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors MMRGlobal
- 05 Jun 2007 Interim results reported at ASCO 2007.
- 14 Dec 2005 New trial record.